A global leader in the development of remote access laboratories and automated lab systems for life science research, Strateos, Inc., has announced the availability of an integrated solution for the design, make, test, and analyze (DMTA) cycles for small molecules.

John Harman, Sr. Director of Product Management at Strateos, said, “Strateos continues to introduce flexible solutions for drug discovery teams seeking state-of-the-art ways to advance small molecule programs. Conventional DMTA cycles are plagued by manual workflows, inadequate scientist-to-scientist communication across labs, less-than-ideal data tracking, slow cycle times, and the capital expense of discovery programs. Our unique cloud-accessible closed-loop system is demonstrating complete DMTA cycles in a handful of days, greatly outpacing the two to three weeks or longer timelines required by either conventional outsourcing methods or internal turn-around times.”

The on-demand, scalable Strateos Cloud Lab Automation-as-a-Service Platform features connected robotic automation utilizing 23 workcells and hundreds of instruments. The platform supports early lead generation through lead optimization choreographed by a software architecture that enables users to design compounds of interest via the cloud, and have the compounds automatically assembled and tested via a variety of methods including cell-based, biochemical, and structured-activity relationships (SAR) assessments.

Daniel Sipes, SVP of Strategy and Operations at Strateos, said, “The Strateos Platform enables the orchestration of scientific workflows and the interactive command and control of our unique fleet of lab automation modules from anywhere in the world, giving researchers the ability to accelerate the DMTA cycle and generate accurate, human and machine-actionable data. We continue to successfully demonstrate these capabilities and show how automating the DMTA cycle enables scientists to work on multiple programs at the same time in parallel, greatly improving process efficiencies and shortening cycle times significantly. The results mirror the benefits we are seeing related to the work we conduct using a DMTA-based approach in synthetic biology and protein engineering applications.”